3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
4
Unknown
2
Terminated
2
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
21
Thoracic
3
Sarcoma
2
NET
2
Lymphoid
2
Head & Neck
2
Endocrine
2
Dermatologic
2
Breast
2
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Head and Neck Neoplasms
276
Squamous Cell Carcinoma of Head and Neck
241
Carcinoma, Non-Small-Cell Lung
86
Melanoma
67
Neoplasms
61
Colorectal Neoplasms
52
Neoplasm Metastasis
48
Carcinoma, Squamous Cell
48
Thyroid Neoplasms
47
Breast Neoplasms
41
Carcinoma, Renal Cell
36
Ovarian Neoplasms
33
Lung Neoplasms
33
Oropharyngeal Neoplasms
30
Stomach Neoplasms
29
Nasopharyngeal Carcinoma
28
Mouth Neoplasms
28
Triple Negative Breast Neoplasms
26
Uterine Cervical Neoplasms
25
Sarcoma
25
Laryngeal Neoplasms
24
Pancreatic Neoplasms
23
Esophageal Neoplasms
23
Salivary Gland Neoplasms
21
Urinary Bladder Neoplasms
20
Recurrence
19
Nasopharyngeal Neoplasms
18
Small Cell Lung Carcinoma
17
Carcinoma, Transitional Cell
17
Prostatic Neoplasms
16
Interventions
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Digestive System Neoplasms
×
Head & Neck
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts
NCT02602067
2018-09-18
Tenatumomab
sigma-tau i.f.r. S.p.A.
Phase 1
Terminated
2 enrolled